BerGenBio

Pre-Annual General Meeting Information • Apr 30, 2024

BerGenBio ASA: Notice of Annual General Meeting

BerGenBio ASA: Notice of Annual General Meeting

Bergen, Norway - 30 April 2024: BerGenBio ASA (OSE:BGBIO) will be holding its

Annual General Meeting virtually on 23 May 2024 at 16:00 hours (CEST).

The notice, registration form and power of attorney are attached to this

release. The notice will be sent to all registered shareholders and the notice

in addition to other attachments are available on the Company's website:

https://www.bergenbio.com/investors/general-meetings

All shareholders are encouraged to exercise their shareholder rights, either

through advance electronically voting through VPS Investor Services, by using

the enclosed proxy form to provide proxy to the Chairman Anders Tullgren (or the

person he appoints), or to attend the general meeting virtually.

Advance vote or proxy for the Annual General Meeting can be registered through

the company's website (https://www.bergenbio.com/investors/general-meetings/) or

VPS Investor

Service (https://investor.vps.no/gm/logOn.htm?token=fb5f16f63e7c413d06d06ff8e1740

3863a2428b1&validTo=1719070200000&oppdragsId=20240208VPPB5UU0) within 21 May

2023 16:00 hours (CEST). Virtual participants need to be logged in to the

meeting before 16:00 hours (CEST) 23 May 2023.

All shareholders will receive a reference number and a pin code required for

registration through the company's website. Reference number and pin code will

be received either by VPS Investor Service or by post depending if the

shareholder is registered as electronical user.

We encourage all shareholders to register as electronical user in VPS.

- END -

AboutBerGenBioASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate bemcentinib a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and severe respiratory infections.

BerGenBiois based in Bergen, Norway with a subsidiary in Oxford, UK. The company

is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information,

visit?www.bergenbio.com

Contacts

Martin Olin, CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.